Following were the major Smallcap losers in the biotech sector on Wednesday. Keep these stocks on your radar this week.
Travere Therapeutics (NASDAQ:TVTX) was one of the notable losers in Wednesday’s trading session with a fall of 13.30% to close at $15.39 and made a new 52-week low of $14.48. The stock saw total volume of over 4 million shares exchanged hands, well above its average volume of 537K shares. The stock came in under pressure after providing a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).
VistaGen Therapeutics (NASDAQ:VTGN) was under pressure on Wednesday as the stock decreased 11.45% to $2.63. After opening at $2.9963, the stock has moved within a wide range of $2.5600 – 2.9963. The stock has gained 36% so far in 2021. On Wednesday, the company announced the initiation of its PALISADE Phase 3 clinical program with the PALISADE-1 Phase 3 trial, a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD).
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) continues to be in downtrend as the stock has seen a major sell-off after hitting a new high of $80.67 earlier this month. . The stock was down 6.68% at $13.68. Earlier this week, the company announced it has completed a $20M financing to progress the development of the mRNA gene editing and cell therapies technology recently licensed from Factor Biosciences and Novellus Therapeutics. Over the past 52-week, the stock moved within a range of $ 2.85 – 28.95. The stock has fallen 70% in the past quarter. The stock is trading 83% below its 52-week high and 628% higher from its 52-week low.